Brainimmunex solution
Targeting the Core for a Fundamental Solution
anti-Brain Aging Medicine via microglia rejuvenation (aBAMmr)
Rejuvenation of Brain Immunity
Diversity of Treatment
Addressing Brain Proteinopathy-Related Diseases
-TDP-43(ALS), Amyloid β(Alzheimer’s Disease), α-Synuclein (Parkinson’s Disease)
Rejuvenative Immunotherapy
“Restoration of Brain Immunity Through Microglia Rejuvenation”
- Avoiding Brain Immune suppression or activation
- Not Targeting a Single Specific Function"
"Brainimmunex adopts a pragmatic yet fundamental research approach, complemented by innovative resources, to pioneer the development of unique and effective therapeutics that distinguish themselves from existing solutions for brain diseases."
Research Capabilities
Brainimmunex stands as a pioneering company, both domestically and internationally, dedicated to advancing innovative treatments for incurable brain diseases. Our focus lies in the technology of brain immune cell rejuvenation, driving brain aging control.
Technology Convergence
With our aBAMmr platform, we are committed to ensuring the sustained success and scalability of our business. This commitment encompasses the sequential development of synthetic new drugs, RNA therapies, and cell therapy pipelines.
Versatility
We anticipate that normalizing brain function through the rejuvenation of brain immune cells will find applications across a spectrum of brain diseases. This approach addresses common risk factors associated with incurable brain diseases, particularly brain aging.